Compare AbbVie Inc (ABBV) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Grab Holdings Ltd. — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Grab Holdings Ltd. trades at $3.81 (market cap $16.07B). The key difference: AbbVie Inc is far larger — about 28× Grab Holdings Ltd.'s market cap, and AbbVie Inc pays a 2.72% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| ABBV | GRAB | |
|---|---|---|
Market Cap | $449.91B | $16.07B |
Sector | Health | Technology |
52-Week High | $261.07 | $6.45 |
52-Week Low | $184.85 | $3.27 |
Enterprise Value | $513.38B | $11.77B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
GRAB trades at $3.93, up 0.77% today, with a bullish technical signal from moving averages. The company achieved profitability in 2025 with net income of $268 million and revenue growth to $3.37 billion. Recent news highlights the departure of Uber's CEO from GRAB's board, causing a brief stock dip. Analyst consensus is strongly bullish with a $5.60 price target, representing significant upside potential from current levels.
GRAB's outlook is positive due to sustained revenue growth and recent profitability, though high P/E of 96.25 suggests elevated expectations. Key risks include competitive pressures in Southeast Asia and reliance on continued user growth. The stock offers growth exposure to the region's digital economy, supported by strong analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
